TrialHepatology international2019

Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India.

Ajit Sood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.